MA50654A - Anticorps anti-pacap - Google Patents

Anticorps anti-pacap

Info

Publication number
MA50654A
MA50654A MA050654A MA50654A MA50654A MA 50654 A MA50654 A MA 50654A MA 050654 A MA050654 A MA 050654A MA 50654 A MA50654 A MA 50654A MA 50654 A MA50654 A MA 50654A
Authority
MA
Morocco
Prior art keywords
pacap antibodies
pacap
antibodies
Prior art date
Application number
MA050654A
Other languages
English (en)
Inventor
Catherine Brautigam Beidler
Michael Parvin Johnson
Chetankumar Natvarlal Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA50654A publication Critical patent/MA50654A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796Receptors; Cell surface antigens; Cell surface determinants for hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050654A 2017-09-29 2018-09-20 Anticorps anti-pacap MA50654A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
MA50654A true MA50654A (fr) 2020-08-05

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050654A MA50654A (fr) 2017-09-29 2018-09-20 Anticorps anti-pacap

Country Status (27)

Country Link
US (3) US10519225B2 (fr)
EP (1) EP3688035A1 (fr)
JP (2) JP6952888B2 (fr)
KR (1) KR102453573B1 (fr)
CN (1) CN111164105B (fr)
AR (1) AR113022A1 (fr)
AU (1) AU2018341959B2 (fr)
BR (1) BR112020003628A2 (fr)
CA (1) CA3077304C (fr)
CL (1) CL2020000705A1 (fr)
CO (1) CO2020002170A2 (fr)
CR (1) CR20200127A (fr)
DO (1) DOP2020000060A (fr)
EA (1) EA202090563A1 (fr)
EC (1) ECSP20020293A (fr)
IL (1) IL273529A (fr)
JO (1) JOP20200069A1 (fr)
MA (1) MA50654A (fr)
MX (1) MX2020003563A (fr)
MY (1) MY199876A (fr)
NZ (1) NZ762312A (fr)
PE (1) PE20201494A1 (fr)
PH (1) PH12020550340A1 (fr)
SG (1) SG11202002572YA (fr)
TW (1) TWI701260B (fr)
WO (1) WO2019067293A1 (fr)
ZA (1) ZA202001058B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6752223B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗pacap抗体及びそれらの抗原結合性断片の使用
CA3020839A1 (fr) * 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anticorps anti-pacap et leurs utilisations
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
JP2024527029A (ja) 2021-07-29 2024-07-19 セファロン リミティド ライアビリティ カンパニー 抗pacap抗体の組成物及び方法
CN117916259A (zh) * 2021-09-30 2024-04-19 江苏恒瑞医药股份有限公司 特异性结合cgrp和pacap的抗原结合分子及其医药用途
KR102839881B1 (ko) * 2021-11-19 2025-07-31 대한민국 방송통신기자재 성능 측정 시스템 및 그 방법
WO2024218541A1 (fr) * 2023-04-20 2024-10-24 Mark Hasleton Traitement de la migraine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE210680T1 (de) * 1990-03-17 2001-12-15 Takeda Chemical Industries Ltd Antikörper gegen hypophysäre adenylatzyklase aktivierende peptid-pacap, hybridome und bestimmung von pacap
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
WO2004062684A2 (fr) 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Inhibition de la signalisation pacap dans la prevention et le traitement de la thrombocytopenie
WO2012106407A2 (fr) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Procédés diagnostiques et thérapeutiques et produits liés aux troubles de l'anxiété
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
TWI636064B (zh) * 2013-03-15 2018-09-21 安美基公司 人類pac1抗體
WO2015023890A1 (fr) 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analogues de pacap/vip glycosylés avec pénétration du snc augmentée pour le traitement de maladies neurodégénératives
JP6752223B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗pacap抗体及びそれらの抗原結合性断片の使用
EP3390447A1 (fr) * 2015-12-15 2018-10-24 Amgen Inc. Anticorps pacap et leurs utilisations
WO2017142961A1 (fr) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Traitement de lésion cérébrale traumatique ou d'accident vasculaire cérébral

Also Published As

Publication number Publication date
JP2022000049A (ja) 2022-01-04
AR113022A1 (es) 2020-01-15
MY199876A (en) 2023-11-27
US20190100579A1 (en) 2019-04-04
KR102453573B1 (ko) 2022-10-12
JOP20200069A1 (ar) 2020-04-28
TWI701260B (zh) 2020-08-11
EA202090563A1 (ru) 2020-06-24
US10954292B2 (en) 2021-03-23
CA3077304C (fr) 2023-08-01
CR20200127A (es) 2020-04-08
TW201920280A (zh) 2019-06-01
US10519225B2 (en) 2019-12-31
AU2018341959B2 (en) 2021-11-25
CO2020002170A2 (es) 2020-04-01
JP2020535167A (ja) 2020-12-03
JP7221352B2 (ja) 2023-02-13
PH12020550340A1 (en) 2022-05-02
PE20201494A1 (es) 2020-12-29
NZ762312A (en) 2022-11-25
CN111164105A (zh) 2020-05-15
SG11202002572YA (en) 2020-04-29
BR112020003628A2 (pt) 2020-09-01
CL2020000705A1 (es) 2020-09-11
EP3688035A1 (fr) 2020-08-05
IL273529A (en) 2020-05-31
US20210171616A1 (en) 2021-06-10
CA3077304A1 (fr) 2019-04-04
MX2020003563A (es) 2020-08-03
WO2019067293A1 (fr) 2019-04-04
JP6952888B2 (ja) 2021-10-27
ECSP20020293A (es) 2020-06-30
US20200131256A1 (en) 2020-04-30
CN111164105B (zh) 2023-07-04
KR20200040881A (ko) 2020-04-20
AU2018341959A1 (en) 2020-03-05
DOP2020000060A (es) 2020-08-15
ZA202001058B (en) 2022-06-29

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
IL272227A (en) Anti-tigit antibodies
EP3589313A4 (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA53434A (fr) Anticorps anti-tigit
IL269405A (en) Anti-sirp alpha antibodies
MA47268A (fr) Anticorps anti-gpc3
EP3498840A4 (fr) Anticorps anti-lag-3
EP3423089A4 (fr) Anticorps anti-tigit
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3661558A4 (fr) Anticorps anti-il1rap
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
MA50352A (fr) Anticorps multispécifiques
MA46057A (fr) Anticorps anti-ctla4
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3691447A4 (fr) Anticorps anti-transthyrétine
EP3492591A4 (fr) Anticorps anti-b7-h4
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3399992A4 (fr) Anticorps autoréticulants
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
MA51134A (fr) Anticorps anti-alpha-synucléine